Royalty Pharma/$RPRX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Royalty Pharma
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
Ticker
$RPRX
Sector
Primary listing
Industry
Pharmaceuticals
Headquarters
Employees
-
ISIN
GB00BMVP7Y09
Website
Royalty Pharma Metrics
BasicAdvanced
$15B
14.39
$2.45
0.48
$0.86
2.50%
Price and volume
Market cap
$15B
Beta
0.48
52-week high
$36.32
52-week low
$24.05
Average daily volume
5.5M
Dividend rate
$0.86
Financial strength
Current ratio
1.558
Quick ratio
1.556
Long term debt to equity
67.618
Total debt to equity
77.819
Dividend payout ratio (TTM)
34.59%
Interest coverage (TTM)
7.71%
Profitability
Gross margin (TTM)
99.06%
Net profit margin (TTM)
48.25%
Operating margin (TTM)
84.00%
Management effectiveness
Return on assets (TTM)
7.05%
Return on equity (TTM)
18.00%
Valuation
Price to earnings (TTM)
14.386
Price to revenue (TTM)
6.354
Price to book
2.24
Price to tangible book (TTM)
2.25
Price to free cash flow (TTM)
56.092
Free cash flow yield (TTM)
1.78%
Free cash flow per share (TTM)
62.88%
Dividend yield (TTM)
2.44%
Forward dividend yield
2.50%
Growth
Revenue change (TTM)
1.13%
Earnings per share change (TTM)
37.60%
3-year revenue growth (CAGR)
-0.21%
3-year earnings per share growth (CAGR)
21.45%
3-year dividend per share growth (CAGR)
6.69%
What the Analysts think about Royalty Pharma
Analyst ratings (Buy, Hold, Sell) for Royalty Pharma stock.
Bulls say / Bears say
Royalty Pharma's strategic acquisition of royalties and milestones on frexalimab, a promising therapy developed by Sanofi for multiple sclerosis and other immune-mediated diseases, enhances its development-stage portfolio and reinforces potential for long-term growth. (stocktitan.net)
The company's strong financial performance in Q4 2024, with Portfolio Receipts reaching $742 million and a 12% growth in Royalty Receipts, driven by key therapies like Evrysdi and Trelegy, indicates robust operational health. (stocktitan.net)
Royalty Pharma's solid liquidity position, with $843 million in cash and cash equivalents and a total debt of $6.3 billion, provides financial stability and flexibility for future investments. (stocktitan.net)
The company's reliance on milestone and other contractual receipts, which saw a 95% year-over-year decline to $31 million in FY 2024, could indicate potential volatility in revenue streams. (royaltypharma.com)
The substantial total debt of $6.3 billion, despite a strong cash position, may raise concerns about leverage and financial risk. (stocktitan.net)
The company's recent $3 billion share repurchase program, while potentially boosting share value, could also be viewed as a sign of limited opportunities for reinvestment in growth initiatives. (stocktitan.net)
Data summarised monthly by Lightyear AI. Last updated on 9 Jun 2025.
Royalty Pharma Financial Performance
Revenues and expenses
Royalty Pharma Earnings Performance
Company profitability
Royalty Pharma News
AllArticlesVideos
Royalty Pharma to pay up to $2 billion to Revolution Medicines for cancer drug
Reuters·3 days ago
Royalty Pharma and Revolution Medicines Enter Into Funding Agreements for Up to $2 Billion
GlobeNewsWire·3 days ago
Royalty Pharma to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
GlobeNewsWire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Royalty Pharma stock?
Royalty Pharma (RPRX) has a market cap of $15B as of June 27, 2025.
What is the P/E ratio for Royalty Pharma stock?
The price to earnings (P/E) ratio for Royalty Pharma (RPRX) stock is 14.39 as of June 27, 2025.
Does Royalty Pharma stock pay dividends?
Yes, the Royalty Pharma (RPRX) stock pays dividends to shareholders. As of June 27, 2025, the dividend rate is $0.86 and the yield is 2.5%. Royalty Pharma has a payout ratio of 34.59% on a trailing twelve-month basis.
When is the next Royalty Pharma dividend payment date?
The next Royalty Pharma (RPRX) dividend payment date is unconfirmed.
What is the beta indicator for Royalty Pharma?
Royalty Pharma (RPRX) has a beta rating of 0.48. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.